On Monday, February 13th, Teva Pharmaceutical (TEVA - Free Report) will release its fourth quarter earnings results after the bell. The company is a Zacks Rank 4 (Sell), and have a Value, Growth, and Momentum score of C.
Dave will look at Teva Pharmaceutical past earnings, looks at what is currently going on with the company, and give us his thoughts on their upcoming earnings announcement.
Furthermore, Dave will uncover some potential options trades for investors looking to make a play on Teva Pharmaceutical ahead of earnings.
Teva Pharmaceutical in Focus
Teva Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.
Teva Pharmaceutical is expected to report earnings at $1.32 per share according to the Zacks Consensus Estimate. Last quarter they met earnings expectations at $1.28 per share. They have an average earnings surprise of 2.59%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
On Monday, February 13th, Teva Pharmaceutical (TEVA - Free Report) will release its fourth quarter earnings results after the bell. The company is a Zacks Rank 4 (Sell), and have a Value, Growth, and Momentum score of C.
Dave will look at Teva Pharmaceutical past earnings, looks at what is currently going on with the company, and give us his thoughts on their upcoming earnings announcement.
Furthermore, Dave will uncover some potential options trades for investors looking to make a play on Teva Pharmaceutical ahead of earnings.
Teva Pharmaceutical in Focus
Teva Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.
Teva Pharmaceutical is expected to report earnings at $1.32 per share according to the Zacks Consensus Estimate. Last quarter they met earnings expectations at $1.28 per share. They have an average earnings surprise of 2.59%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on TEVA - FREE